Dermocin Ointment (Mupirocin) is an antibiotic produced through fermentation of Pseudomonas fluorescens. It is active against a wide range of bacteria responsible for the majority of skin infections.
Dermocin Ointment (Mupirocin) is an antibiotic produced through fermentation of Pseudomonas fluorescens. It is active against a wide range of bacteria responsible for the majority of skin infections, e.g. Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA), other Staphylococci, and Streptococci. It inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Due to this particular mode of action and its unique chemical structure, Mupirocin does not show any cross-resistance with other clinically available antibiotics. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations (MIC) and bactericidal properties at the higher concentrations reached when applied locally.
Dermocin Ointment: Each gram of ointment contains Mupirocin USP 20 mg.
Dermocin (Mupirocin) Ointment is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes Prophylactically, Dermocin Ointment may be used to prevent bacterial contamination in minor burns, biopsy sites, incisions and other clean lesions. For abrasions, minor cuts, and wounds the prophylactic use of Dermocin may prevent the development of infection and permit wound healing.
A small amount of Dermocin (Mupirocin) Ointment should be applied to the affected area three times daily. The area treated may be covered with gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.
Dermocin ointment should not be given to patients with a history of hypersensitivity to any of its constituents.
Dermocin Ointment is not for ophthalmic or intra-nasal use. If a reaction suggesting sensitivity or chemical irritation occurs with the
use of Dermocin (Mupirocin) Ointment, treatment should be discontinued and appropriate alternative therapy for the infection
should be instituted. As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible
organisms, including fungi. When Dermocin (Mupirocin) is used on the face care should be taken to avoid the eyes.
The following local adverse reactions have been reported in connection with the use of Dermocin (Mupirocin) Ointment: burning, stinging, or pain in 1.5% of patients; itching in 1% of patients; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of patients.
The effect of the concurrent application of Dermocin (Mupirocin) and other drug products has not been studied.
Use in Pregnancy: The drug is classified in Pregnancy Category B. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Use in Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Dermocin (Mupirocin) is administered to a nursing woman.
Pediatric Use: The safety and effectiveness of Dermocin (Mupirocin) have been established in the age range of 2 months to 16 years. The use of the ointment in these age groups is supported by evidence from adequate and well-controlled studies of Mupirocin in impetigo in pediatric patients.
Dermocin Ointment: Each tube contains 10 g ointment.
FR
DE
